Leerink Swann Downgrades Waters, Noting Macroeconomic Environment and Soft End Markets | GenomeWeb

NEW YORK (GenomeWeb News) – Leerink Swann downgraded Waters today to Market Perform, saying the company could be challenged by the macroeconomic environment and softer end-markets, as well as increasing competition for its products and services.

Analyst Dan Leonard downgraded the company from a prior rating of Outperform, though he kept the valuation on Waters' stock in the $88 to $89 range.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.